Description

Alnylam Pharmaceuticals: Reinventing ATTR Treatment Through RNAi Silencing and Expanding Patient Adoption!

Alnylam Pharmaceuticals reported its first quarter 2026 results marked by continued revenue growth and pipeline progress, reflecting ongoing commercial and research execution challenges and opportunities. The company achieved a record combined net product revenue exceeding $1 billion, an increase of 121% year-over-year and 4% sequentially, driven primarily by its transthyretin amyloidosis (TTR) franchise. The TTR portfolio, consisting of AMVUTTRA and ONPATTRO, generated $910 million in Q1 revenues, growing 153% year-over-year and 6% from the prior quarter. In the U.S., TTR revenues expanded by 9% sequentially and more than 230% year-over-year, with demand growth partially offset by fewer selling weeks and customary insurance reauthorization dynamics. Internationally, revenues declined slightly from Q4 due to a pricing update in Germany but increased 35% year-over-year, led by growth in Japan and polyneuropathy indications. Rare disease revenues also grew 15% year-over-year to $126 million but faced some margin pressure due to increasing gross-to-net deductions.